74 related articles for article (PubMed ID: 19887873)
21. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Chang JW; Chou CL; Huang SF; Wang HM; Hsieh JJ; Hsu T; Cheung YC
Lung Cancer; 2007 Dec; 58(3):414-7. PubMed ID: 17618013
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Cho BC; Im CK; Park MS; Kim SK; Chang J; Park JP; Choi HJ; Kim YJ; Shin SJ; Sohn JH; Kim H; Kim JH
J Clin Oncol; 2007 Jun; 25(18):2528-33. PubMed ID: 17577030
[TBL] [Abstract][Full Text] [Related]
23. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Hata A; Katakami N; Yoshioka H; Fujita S; Kunimasa K; Nanjo S; Otsuka K; Kaji R; Tomii K; Iwasaku M; Nishiyama A; Hayashi H; Morita S; Ishida T
Lung Cancer; 2011 Nov; 74(2):268-73. PubMed ID: 21529987
[TBL] [Abstract][Full Text] [Related]
24. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Leighl NB; Tsao WS; Zawisza DL; Nematollahi M; Shepherd FA
Lung Cancer; 2006 Jan; 51(1):115-21. PubMed ID: 16188343
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
26. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
27. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
[TBL] [Abstract][Full Text] [Related]
28. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
Uramoto H; Sugio K; Oyama T; Ono K; Sugaya M; Yoshimatsu T; Hanagiri T; Morita M; Yasumoto K
Lung Cancer; 2006 Jan; 51(1):71-7. PubMed ID: 16198442
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
[TBL] [Abstract][Full Text] [Related]
32. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.
Sugio K; Uramoto H; Onitsuka T; Mizukami M; Ichiki Y; Sugaya M; Yasuda M; Takenoyama M; Oyama T; Hanagiri T; Yasumoto K
Lung Cancer; 2009 Jun; 64(3):314-8. PubMed ID: 18992959
[TBL] [Abstract][Full Text] [Related]
33. Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.
Zampa G; Moscato M; Brannigan BW; Morabito A; Bell DW; Normanno N
Lung Cancer; 2008 Jun; 60(3):452-4. PubMed ID: 18079016
[TBL] [Abstract][Full Text] [Related]
34. [Long-term remission after erlotinib therapy in an elderly patient with advanced non-small-cell lung cancer. Case report and conclusions for clinical practice].
Duchnowska R; Siemiatkowska A; Grala B; Smoter M
Pneumonol Alergol Pol; 2008; 76(6):451-5. PubMed ID: 19173195
[TBL] [Abstract][Full Text] [Related]
35. EGFR-TKI treatment and surgical resection for oligometastatic NSCLC?
Klomp HM; Kappers I
Onkologie; 2009 Nov; 32(11):627-8. PubMed ID: 19887865
[No Abstract] [Full Text] [Related]
36. Pathological complete response to gefitinib in a 10-year-old boy with EGFR-negative pulmonary mucoepidermoid carcinoma: a case report and literature review.
Li S; Zhang Z; Tang H; He Z; Gao Y; Ma W; Chang Y; Wei B; Ma J; Liu K; Ma Z; Wang Q
Clin Respir J; 2017 May; 11(3):346-351. PubMed ID: 26148572
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases.
Hishida T; Yoshida J; Aokage K; Nagai K; Tsuboi M
Gen Thorac Cardiovasc Surg; 2016 Jul; 64(7):429-33. PubMed ID: 25512091
[TBL] [Abstract][Full Text] [Related]
38. Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case.
Kataoka K; Osaka E; Shimizu T; Okamura Y; Yoshida Y; Tokuhashi Y
Thorac Cancer; 2016 Nov; 7(6):676-680. PubMed ID: 27755795
[TBL] [Abstract][Full Text] [Related]
39. Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib.
Govindan R; Behnken D; Read W; McLeod H
Ann Oncol; 2003 Aug; 14(8):1330-1. PubMed ID: 12881402
[No Abstract] [Full Text] [Related]
40. Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer.
Hashimoto K; Horinouchi H; Ohtsuka T; Kohno M; Izumi Y; Hayashi Y; Nomori H
Gen Thorac Cardiovasc Surg; 2012 Dec; 60(12):851-4. PubMed ID: 22688581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
